(Q48275264)

10 February 2018

meta-analysis

0 references

title

Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder (English)

1 reference

10 February 2018

1 reference

1

1 reference

10 February 2018

author name string

Ana Garcia Lopez

series ordinal

2

1 reference

10 February 2018

language of work or name

English

0 references

publication date

2 November 2011

1 reference

10 February 2018

published in

Advances in Therapy

1 reference

10 February 2018

volume

28

1 reference

10 February 2018

issue

11

1 reference

10 February 2018

page(s)

1021-1037

1 reference

10 February 2018

EEG sleep studies in patients with generalized anxiety disorder

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Suicide risk assessment: a review of risk factors for suicide in 100 patients who made severe suicide attempts. Evaluation of suicide risk in a time of managed care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

The effect of escitalopram on sleep problems in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

The effects of antidepressants on sleep: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Sleep disturbance in anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Insomnia and depression: a multifaceted interplay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Comorbidity of insomnia and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Depression and poor sleep: the effect of monoaminergic antidepressants in a pre-clinical model in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Escitalopram versus citalopram: the surprising role of the R-enantiomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Co-prescription of antidepressants with other psychotropics: Distinct profile of escitalopram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

Good night and good luck: norepinephrine in sleep pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0071-8

10.1007/S12325-011-0071-8

21 January 2018

Identifiers

DOI

1 reference

10 February 2018

1 reference

10 February 2018